SCHEMBL25517519

SCHEMBL25517519

COc1ccccc1NC(=S)Nc1ccc(C)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.63
GAA P10253 3/20 0.62
ALDH1A1 P00352 7/20 0.60
KMT2A Q03164 4/20 0.60
MAPT P10636 3/20 0.60
ALOX12 P18054 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MEN1 O00255 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
LMNA P02545 1/20 0.59
POLB P06746 1/20 0.59
HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17956756 0.89 GAA (0.71) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL3822985 0.87 HPGD (0.80) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL31388324 0.87 HPGD (0.80) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL7945600 0.86 ALDH1A1 (0.62) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL6816152 0.85 KMT2A (0.71) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL9620979 0.83 ALDH1A1 (0.79) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL17079608 0.82 ALDH1A1 (0.71) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL7945596 0.81 SMN1; SMN2 (0.76) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL5852135 0.81 MAPT (0.78) HPGDGAAALDH1A1KMT2AMAPT
SCHEMBL28401848 0.80 ALDH1A1 (0.73) HPGDGAAALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML HPGD 4591/4885GAA 2575/4885ALDH1A1 4846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.